The increasing pressure on health resources has led to the emergence of risk assessment as an essential tool in the management of cardiovascular disease (CVD). Concern exists regarding the validity of their generalization to all populations. Existing risk scoring models do not incorporate emerging ‘novel’ risk factors. In this context, the aim of the study was to examine the relevance of British, European, and Framingham predictive CVD risk scores to the asymptomatic high risk Indian population. Encore Usb Tv Tuner Driver. Blood samples drawn from the participants were analyzed for various ‘traditional’ and ‘novel’ biomarkers, and their CVD risk factor profiling was also done. The Framingham model defined only 5% of the study cohort to be at high risk, which appears to be an underestimation of CVD risk in this genetically predisposed population. These subjects at high risk had significantly elevated levels of lipid, pro-inflammatory, pro-thrombotic, and serological markers.
Separate calculators for men and women. National Cholesterol Education Program. (NCEP) Adult Treatment Panel III (ATP. III) risk assessment tool based on. Framingham Heart Study • Calculates 10-year risk for myocardial infarction and coronary death. • For adults 20 years and. Score should be derived from a population free from treatment. The lack of accounting for treatment effect and the wide variation in study characteristics, predictors and outcomes causes difficulties in the use of cardiovascular risk scores for clinical treatment decision. For many years, the Framingham.
It is more relevant to develop risk predictive scores for application to the Indian population. This study substantiates the argument that alternative approaches to risk stratification are required in order to make them more adaptable and applicable to different populations with varying risk factor and disease patterns. Introduction Atherosclerotic cardiovascular disease (CVD) resulted in 17.5 million deaths in 2005, representing 30% of all the global deaths (). Despite major advances in treatment of ischemic heart disease (IHD) patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. Available screening and diagnostic methods are insufficient to identify the victims before the event occurs. The first detectable clinical manifestation of atherosclerosis is often a clinical event: a stroke or myocardial infarction (MI).